Table 3

Biomarker levels at baseline and percentage changes in biomarkers from baseline to week 22 in patients stratified according to baseline ASDAS and BASDAI

Baseline ASDASBaseline BASDAI
Moderate/high ASDAS (≥1.3 and ≤3.50) N=18Very high ASDAS (>3.50) N=32Moderate BASDAI (>30 and <50) N=21High BASDAI (≥50) N=32
Week 0% Week 0–22Week 0% Week 0–22Week 0% Week 0–22Week 0% Week 0–22
CRP (mg/l)8 (3.4; 13)***−57 (−73; 7)**26 (15; 49)−86 (−96; −62)12 (3.9; 22)−61 (−85; −35)22 (10; 44)−86 (−94; −45)
IL-6 (ng/l)4.5 (3.4; 8)*−55 (−81; −6)**10 (4.1; 25)−83 (−93; −69)5 (3.7; 11)−74 (−84; −16)9 (3.7; 24)−80 (−91; −62)
VEGF (ng/l)36 (24; 83)***−10 (−29; 16)**98 (50; 205)−36 (−60; −20)52 (25; 125)−10 (−37; 7)*82 (42; 203)−39 (−59; −20)
YKL-40 (μg/l)55 (43; 102)−15 (−43; 2)42 (34; 68)−15 (−39; 0)57 (42; 99)−17 (−36; 0)42 (33; 69)−13 (−42; 4)
CTX-II (ng/mmol)445 (242; 845)−21 (−43; −8)485 (280; 853)−18 (−58; 34)419 (246; 629)−20 (−44; −4)516 (281; 893)−18 (−58; 34)
Aggrecan (µg/l)592 (442; 732)2 (−8; 13)*543 (455; 717)10 (3; 26)577 (422; 715)3 (−8; 13)564 (480; 749)10 (1; 21)
MMP-3 (µg/l)23 (14; 27)−11 (−25; 20)*32 (17; 117)−33 (−68; 5)23 (15; 37)−11 (−27; 4)29 (15; 61)−36 (−65; 9)
COMP (µg/l)1.50 (1.37; 1.85)4 (−11; 25)1.70 (1.35; 1.95)7 (−5; 15)1.50 (1.28; 1.78)7 (−3; 22)1.68 (1.50; 1.94)3 (−5; 14)
CTX-I (µg/l)0.34 (0.23; 0.75)−9 (−28; 22)0.31 (0.23; 0.45)−6 (−30; 17)0.31 (0.23; 0.56)−9 (−26; 32)0.38 (0.24; 0.46)−5 (−29; 13)
Osteocalcin (µg/l)30.5 (18.5; 44.2)2 (−25; 14)25.4 (20.1; 29.1)9 (−9; 29)26.5 (21.3; 44.9)3 (−19; 15)25.6 (21.1; 30.5)10 (−9; 29)
  • Biomarker levels are median (IQR). Mann–Whitney test for comparison of baseline biomarker levels and for percentage change between baseline and week 22: *p<0.05; **p<0.01; ***p<0.001. The analyses included 53 patients because seven patients were excluded before week 22. Of the patients followed to week 22, ASDAS could not be determined in three patients at baseline.

    ASDAS, ankylosing spondylitis disease activity score; BASDAI, Bath ankylosing spondylitis disease activity index; COMP, cartilage oligomeric matrix protein; CRP, C-reactive protein; CTX-I, C-terminal cross-linking telopeptide of type I collagen; CTX-II, C-terminal crosslinking telopeptide of type II collagen; IL-6, interleukin 6; MMP-3, matrix metalloproteinase 3; VEGF, vascular endothelial growth factor.